Cargando…
Blood-based extracellular matrix biomarkers as predictors of survival in patients with metastatic pancreatic ductal adenocarcinoma receiving pegvorhyaluronidase alfa
BACKGROUND: Extensive extracellular matrix (ECM) remodeling is a hallmark of metastatic pancreatic ductal adenocarcinoma (mPDA). We investigated fragments of collagen types III (C3M, PRO-C3), VI (PRO-C6), and VIII (C8-C), and versican (VCANM) in plasma as biomarkers for predicting progression-free s...
Autores principales: | Wang, Song, Bager, Cecilie L., Karsdal, Morten A., Chondros, Dimitrios, Taverna, Darin, Willumsen, Nicholas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7819178/ https://www.ncbi.nlm.nih.gov/pubmed/33478521 http://dx.doi.org/10.1186/s12967-021-02701-z |
Ejemplares similares
-
Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma
por: Van Cutsem, Eric, et al.
Publicado: (2020) -
Matrix Metalloprotease Generated Fragments of Type VI Collagen Have Serum Biomarker Potential in Cancer – A Proof of Concept Study
por: Willumsen, Nicholas, et al.
Publicado: (2019) -
Safety and pharmacokinetics of docetaxel in combination with pegvorhyaluronidase alfa in patients with non‐small cell lung cancer
por: Heineman, Thomas, et al.
Publicado: (2021) -
Extracellular matrix specific protein fingerprints measured in serum can separate pancreatic cancer patients from healthy controls
por: Willumsen, Nicholas, et al.
Publicado: (2013) -
Regulation of tumor immunity and immunotherapy by the tumor collagen extracellular matrix
por: Flies, Dallas B., et al.
Publicado: (2023)